Abstract
Overcoming myelodysplastic syndrome progression after frontline therapy.
Highlights
Analyses of primary myelodysplastic syndrome (MDS) samples from the largest cohort ever evaluated demonstrate that the hematopoietic stem cell populations that originate Myelodysplastic syndromes (MDSs) have distinct differentiation phenotypes and associated signaling pathways
Studies with advanced sequencing technologies have shown that cells in the hematopoietic stem cells (HSCs) compartment drive MDS progression[5], but how they contribute to therapy failure and disease evolution is unknown
To investigate the mechanistic basis of MDS progression, we elucidated the biological properties of MDS HSCs and identified survival and proliferation pathways that are specific to distinct MDS HSC populations and that could be therapeutically targeted
Summary
Analyses of primary myelodysplastic syndrome (MDS) samples from the largest cohort ever evaluated demonstrate that the hematopoietic stem cell populations that originate MDS have distinct differentiation phenotypes and associated signaling pathways. These differences can be targeted with selective therapies that could benefit patients with progressed disease. This is a summary of: Ganan-Gomez, I. et al Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.